source
- Merck's Lipfendra pill receives FDA approval as first oral PCSK9 cholesterol treatmentThe U.S. Food and Drug Administration approved Lipfendra, an oral medication from Merck that lowers low density lipoprotein cholesterol. The drug blocks the PCSK9 protein, making it the first pill…
- Merck wins FDA nod for first oral PCSK9 inhibitor, Lipfendra, to treat high LDL cholesterolMerck announced that the U.S. Food and Drug Administration has approved its once-daily oral PCSK9 inhibitor, enlicitide, marketed as Lipfendra, for adults with elevated LDL cholesterol. The drug i…